**ESG in the Investment Industry**

- The SEC is seeking comments to guard against the misleading use of ESG.
  - The SEC posed numerous questions on how and under what circumstances the “names rule” should apply to investments marketed as ESG or Sustainable.
- MSCI highlighted the expected escalation of regulating ESG investing in its annual *ESG Trends to Watch* report.
- Climate change and a focus on sustainable, diverse, and inclusive workplaces were among the central topics at the 2020 World Economic Forum meeting in Davos.
- US utilities increasingly emphasized their growing clean energy portfolios and greenhouse gas (GHG) emission reductions to appease investors.
- Numerous companies across multiple sectors pledged lofty carbon-neutral goals.

**The Renewed Social Focus**

- As the world deals with market turbulence and the global health crisis, the situation has begun to shed light on how companies treat their stakeholders.
  - The social aspect of ESG has come to the forefront, and a company’s reaction today could have major impacts on both its long-term image and the speed of the eventual economic recovery.
  - Many companies have been forced to reevaluate policies impacting human capital, such as paid sick leave, executive compensation, and health care benefits.
- The well-being and safety of employees, particularly in the health care sector, delivery services, and grocery stores, is a major focus during the pandemic.
  - Some employees are threatening a “sick-out” to protest the lack of protections offered.

**Characteristics**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Bloomberg Barclays US Aggregate (Agg) &amp; MSCI Focused Sub-Indices</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Standard</td>
</tr>
<tr>
<td>Yield to Worst</td>
<td>1.59</td>
</tr>
<tr>
<td>Duration</td>
<td>5.69</td>
</tr>
<tr>
<td>Spread</td>
<td>95</td>
</tr>
<tr>
<td>Convexity</td>
<td>0.41</td>
</tr>
<tr>
<td>1-Yr Return (%)</td>
<td>11.68</td>
</tr>
</tbody>
</table>

**ESG Monitor**

**First Quarter 2020**

**Keeping Sight of ESG**

- While it is hard to see past current market conditions, we acknowledge that ESG factors will continue to be a key element of sound fundamental credit analysis.
- Recent headlines emphasizing the positive environmental impacts from the reduced GHG emissions due to the pandemic don’t always tell the full story.
  - The consumption of oil dropped significantly late in the quarter as much of the workforce shifted to working remotely or lost their jobs altogether. While fewer are driving, reduced oil prices provide consumers temporary relief at the pumps.
  - Although temporary, reduced demand should lead to improved air quality and reduced emissions but will most likely not lead to a sustainable decrease in pollution.
  - Significant increase in both household and medical waste is expected throughout the pandemic, offsetting or even surpassing any benefits from the reduction in GHG.
  - Lower oil prices could test the longer-term viability of some high-cost renewable energy projects as companies struggle to maintain their core operations.
- The EPA has temporarily suspended enforcement of federally mandated public health and environmental protections.
- The expected stimulus for recovery could be an opportunity for the government and private companies to utilize green investments and focus on more efficient solutions.

**ESG Headline Events**

- Oil demand is estimated to have fallen as much as 20% globally since last year.
- Demand is expected to remain down as the world battles the spread of the coronavirus.

- ESG factors influence headlines and can impact credit performance. Social factors have been prevalent in the media recently.

- Cox Communications, the largest private telecom serving six million homes and businesses, upgraded internet speeds for residential customers and is providing additional support and relief as many transition to work and learning from home.

- Following negative backlash in the media, Gilead Sciences waived all benefits that accompany the ‘orphan status’ of its antiviral drug Remdesivir, which has potential to treat COVID-19 patients, allowing generic drug makers to produce a low-cost version¹.

---

¹ This abstract from the *Financial Times* was produced by IR+M
The views contained in this report are those of Income Research & Management ("IR+M") and are based on information obtained by IR+M from sources that are believed to be reliable. This report is for informational purposes only and is not intended to provide specific advice, recommendations, or projected returns for any particular IR+M product. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission from Income Research & Management.

BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively “Bloomberg”). BARCLAYS® is a trademark and service mark of Barclays Bank Plc (collectively with its affiliates, “Barclays”), used under license. Bloomberg or Bloomberg’s licensors, including Barclays, own all proprietary rights in the Bloomberg Barclays Indices. Neither Bloomberg nor Barclays approves or endorses this material, or guarantees the accuracy or completeness of any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith.

Copyright © 2020, S&P Global Market Intelligence. Reproduction of any information, data or material, including ratings (“Content”) in any form is prohibited except with the prior written permission of the relevant party. Such party, its affiliates and suppliers (“Content Providers”) do not guarantee the accuracy, adequacy, completeness, timeliness or availability of any Content and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such Content. In no event shall Content Providers be liable for any damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with any use of the Content. A reference to a particular investment or security, a rating or any observation concerning an investment that is part of the Content is not a recommendation to buy, sell or hold such investment or security, does not address the suitability of an investment or security and should not be relied on as investment advice. Credit ratings are statements of opinions and are not statements of fact.